title: Abnormal expression and function of Fas ligand of lacrimal glands and peripheral blood in Sjögren's syndrome patients with enlarged exocrine glands.
abstract: The objective of our study was to investigate the possibility of Fas ligand protein abnormalities in certain types of Sjögren's syndrome patients with enlarged exocrine glands. Fas ligand expression by lymphocytes infiltrating the lacrimal glands and by peripheral blood monocytes in Sjögren's syndrome patients with enlarged exocrine glands was assessed immunohistologically and by immunoblotting. Cytotoxicity of peripheral blood monocytes and sensitivity to steroids in Sjögren's syndrome patients with enlarged exocrine glands were studied by functional assay. Minimal Fas ligand expression was detected in the lymphocytes of the lacrimal glands and a decreased level of Fas ligand was found in peripheral blood monocytes as assessed by immunoblotting. Functional assay confirmed the decreased cytotoxicity of lymphocytes in Sjögren's syndrome patients with enlarged exocrine glands, and that it is not affected by anti-Fas ligand antibody. By contrast, the sensitivity of lymphocytes in Sjögren's syndrome patients with enlarged exocrine glands to steroids was increased. These observations suggest that abnormal expression and function of Fas ligand occurs in Sjögren's syndrome patients with enlarged exocrine glands.
authors.affiliation: Department of Ophthalmology, Tokyo Dental College, Sugano 5-11-13 Ichikawa-shi, Chiba 272-8513, Japan. tsubota@tdc.ac.jp
authors.forename: K
authors.initials: K
authors.lastname: Tsubota
authors.forename: H
authors.initials: H
authors.lastname: Fujita
authors.forename: K
authors.initials: K
authors.lastname: Tadano
authors.forename: N
authors.initials: N
authors.lastname: Onoda
authors.forename: K
authors.initials: K
authors.lastname: Tsuzaka
authors.forename: T
authors.initials: T
authors.lastname: Takeuchi
mesh_terms: D000305:Adrenal Cortex Hormones / Q000494:pharmacology; D000328:Adult; D000368:Aged; D017209:Apoptosis / Q000235:genetics*; D001327:Autoimmune Diseases / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D015551:Autoimmunity / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D004351:Drug Resistance; D015352:Dry Eye Syndromes / Q000209:etiology / Q000378:metabolism / Q000473:pathology*; D005088:Exocrine Glands / Q000473:pathology; D053222:Fas Ligand Protein; D005260:Female; D006801:Humans; D016130:Immunophenotyping; D007765:Lacrimal Apparatus / Q000378:metabolism / Q000473:pathology*; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D016131:Lymphocyte Subsets / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood / Q000172:deficiency* / Q000235:genetics / Q000502:physiology; D008875:Middle Aged; D012859:Sjogren's Syndrome / Q000235:genetics / Q000378:metabolism / Q000473:pathology*
chemical_list: D000305:Adrenal Cortex Hormones; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins